Pfizer 4Q Revenues: $13.7 billion (+1%) 4Q Earnings: $12.3 billion (earnings were $775 million 4Q16) FY Revenues: $52.5 billion (-1%) FY Earnings: $21.3 billion (earnings were $7.2 billion FY16) Comments: Innovative Health sales were up 6% in the quarter to $8.2 billion, driven by continued growth from key brands including Eliquis, Xeljanz, Prevenar 13, as well as Lyrica, Ibrance and Chantix/Champix. Eliquis sales were $710 million in the quarter, up 46%. Xeljanz sales were up 47% to $410 m...